BioPharma Credit PLC
BOPCF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $124,457 | $159,682 | $213,771 | $126,394 |
| % Growth | -22.1% | -25.3% | 69.1% | – |
| Cost of Goods Sold | $25,571 | $25,243 | $33,895 | $15,892 |
| Gross Profit | $124,457 | $110,487 | $184,245 | $87,969 |
| % Margin | 100% | 69.2% | 86.2% | 69.6% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $1,969 | $1,861 | $1,698 | $2,857 |
| SG&A Expenses | $2,149 | $2,036 | $1,898 | $3,057 |
| Sales & Mktg Exp. | $180 | $175 | $200 | $200 |
| Other Operating Expenses | $130 | $1 | $36 | -$47 |
| Operating Expenses | $2,279 | $2,037 | $1,934 | $3,010 |
| Operating Income | $122,178 | $108,450 | $182,311 | $84,959 |
| % Margin | 98.2% | 67.9% | 85.3% | 67.2% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | $122,178 | $108,450 | $182,311 | $84,959 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $122,178 | $108,450 | $182,311 | $84,959 |
| % Margin | 98.2% | 67.9% | 85.3% | 67.2% |
| EPS | 0.1 | 0.083 | 0.13 | 0.062 |
| % Growth | 20.8% | -36.3% | 110.4% | – |
| EPS Diluted | 0.1 | 0.083 | 0.13 | 0.062 |
| Weighted Avg Shares Out | 1,222,360 | 1,309,410 | 1,373,932 | 1,373,932 |
| Weighted Avg Shares Out Dil | 1,222,360 | 1,309,410 | 1,373,932 | 1,373,932 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,490 | $4,324 | $1,145 | $3,131 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | -$122,180 | -$108,457 | -$182,340 | -$84,977 |
| EBITDA | $122,178 | $0 | $0 | $0 |
| % Margin | 98.2% | 0% | 0% | 0% |